Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea

Condition studied

Essential Thrombocythemia

Eligibility

Primary endpoint

Percentage of patients achieving a reduction of platelet counts to ≤400x109/L in the absence of any subsequent thrombotic events while maintaining normal platelet counts, at any time during 24 weeks of treatment, Occurrence, severity of Treatment Emergent Adverse Events (TEAEs) (graded using the Common Terminology Criteria for AEs -CTCAE) v 5.0 criteria